Current Trends in the Epidemiological and Pathological Characteristics of Gastrointestinal Stromal Tumors in Korea, 2003-2004.
- Author:
Mee Yon CHO
1
;
Jin Hee SOHN
;
Joon Mee KIM
;
Kyoung Mee KIM
;
Young Su PARK
;
Woo Ho KIM
;
Jin Sook JUNG
;
Eun Sun JUNG
;
So Young JIN
;
Dae Young KANG
;
Jae Bok PARK
;
Ho Sung PARK
;
You Duck CHOI
;
Sun Hee SUNG
;
Young Bae KIM
;
Hogeun KIM
;
Young Kyung BAE
;
Miseon KANG
;
Hee Jin CHANG
;
Yang Seok CHAE
;
Hee Eun LEE
;
Do Youn PARK
;
Youn Soo LEE
;
Yun Kyung KANG
;
Hye Kyung KIM
;
Hee Kyung CHANG
;
Soon Won HONG
;
Young Hee CHOI
;
Okran SHIN
;
MiJin GU
;
Youn Wha KIM
;
Gwang Il KIM
;
Sei Jin CHANG
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Gastrointestinal Stromal Tumors; Epidemiology; Pathology; Prognosis
- From:Journal of Korean Medical Science 2010;25(6):853-862
- CountryRepublic of Korea
- Language:English
- Abstract: Despite remarkable progress in understanding and treating gastrointestinal stromal tumors (GISTs) during the past two decades, the pathological characteristics of GISTs have not been made clear yet. Furthermore, concrete diagnostic criteria of malignant GISTs are still uncertain. We collected pathology reports of 1,227 GISTs from 38 hospitals in Korea between 2003 and 2004 and evaluated the efficacy of the NIH and AFIP classification schemes as well as the prognostic factors among pathologic findings. The incidence of GISTs in Korea is about 1.6 to 2.2 patients per 100,000. Extra-gastrointestinal GISTs (10.1%) are more common in Korea than in Western countries. In univariate analysis, gender, age, tumor location, size, mitosis, tumor necrosis, vascular and mucosal invasions, histologic type, CD34 and s-100 protein expression, and classifications by the NIH and AFIP criteria were found to be significantly correlated with patient's survival. However, the primary tumor location, stage and classification of the AFIP criteria were prognostically significant in predicting patient's survival in multivariate analysis. The GIST classification based on original tumor location, size, and mitosis is more efficient than the NIH criteria in predicting patient's survival, but the mechanism still needs to be clarified through future studies.
